Arexvy: A Comprehensive Review of the Respiratory Syncytial Virus Vaccine for Revolutionary Protection
Author:
- 1 January 2024
- journal article
- review article
- Published by SAGE Publications in Viral Immunology
- Vol. 37 (1) , 12-15
Abstract
The respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infection in children and poses a significant risk to older adults. Developing a vaccine against RSV has been a priority, and the recently approved Arexvy vaccine has shown promise in preventing lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older. This comprehensive review discusses the history of RSV, challenges in vaccine development, and the mechanism of action of Arexvy. The efficacy and safety of the vaccine are explored based on phase 3 clinical trial, demonstrating its effectiveness in preventing RSV-associated LRTD. The most common adverse reactions reported include injection site pain, fatigue, myalgia, headache, and arthralgia. Ongoing research focuses on the long-term effectiveness of Arexvy, including the need for booster doses and its impact on reducing RSV-associated hospitalizations. The potential of Arexvy to lessen the burden of RSV-related illnesses, particularly in vulnerable populations, is highlighted, emphasizing the importance of widespread immunization efforts and accessibility to this groundbreaking vaccine.Keywords
This publication has 24 references indexed in Scilit:
- Respiratory syncytial virus: current and emerging treatment optionsClinicoEconomics and Outcomes Research, 2014
- Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial VirusScience, 2013
- Respiratory syncytial virus prevention and therapy: Past, present, and futurePediatric Pulmonology, 2010
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- RSV604, a Novel Inhibitor of Respiratory Syncytial Virus ReplicationAntimicrobial Agents and Chemotherapy, 2007
- Immunoglobulin treatment for respiratory syncytial virus infection2006
- Respiratory Syncytial Virus Infection in Elderly and High-Risk AdultsNew England Journal of Medicine, 2005
- Risk of Primary Infection and Reinfection With Respiratory Syncytial VirusArchives of Pediatrics & Adolescent Medicine, 1986
- An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderlyJournal of Infection, 1984
- An outbreak of respiratory syncytial virus infection in an old people's homeJournal of Infection, 1984